CSA Medical Hires Vice President of Medical

CSA Medical Inc. has added to its executive team.

The company has appointed Stephen Mascioli, M.D., as vice president of Medical. In this newly created role, Mascioli will provide clinical and medical oversight to the commercial truFreeze franchise, including physician training and education, research and customer support programs.

“Dr. Mascioli has a wealth of experience as a medical device executive and physician scientist at both early stage and established organizations, and we are thrilled to have him join our team,” said Bill Floyd, president/CEO. “We believe his experience managing clinical, regulatory and quality programs across the full spectrum of the medical product life cycle will be tremendously valuable as we work to expand the utilization of spray cryotherapy to benefit more patients.”

Mascioli brings to CSA Medical more than 25 years of experience within the medical device industry. Prior to joining CSA Medical, he served as vice president and chief medical officer at Terumo Americas Holdings, a Japanese global medical device company, where he managed patient safety issues, created a medical department and led field-based clinical support. Previously he was chief medical officer at Covidien plc for its Vascular Therapies division. In this position he managed clinical affairs, healthcare economics and reimbursement, professional education and professional relations programs. He also served as medical director of Medical Sciences for Boston Scientific Corp.’s Cardiovascular Clinical Sciences group.

Earlier in his career, Mascioli held clinical and medical management positions at several early-stage and startup companies, including Advanced Bio-Surfaces Inc., First Circle Medical Inc., American Medical Systems and Cherne Medical Inc. He has published 24 manuscripts in peer-reviewed journals spanning cardiovascular disease and other areas. Mascioli holds a master’s of Public Heath in Epidemiology from the University of Minnesota and a doctorate of Medicine from Boston University Medical School. He is certified by the American Board of Internal Medicine and completed his residency at the University of Minnesota Hospitals.

“The clinical experience and growing body of clinical evidence in support of CSA Medical’s spray cryotherapy platform is compelling, and I believe that there is a tremendous opportunity to help further advance care and quality of life for patients with this technology,” said Mascioli. “I look forward to working with my colleagues to realize the fullest potential for this technology.”

CSA Medical develops spray cryotherapy medical device solutions that flash freeze and destroy unwanted tissue inside the body. The Lutherville, Md.-based company claims is the first to harness the power of low pressure, extremely cold (-196 degrees Celsius) liquid nitrogen spray inside the body.